SCHEMBL20304553

SCHEMBL20304553

CCOc1ncc(F)cc1S(=O)(=O)Cl

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALPL P05186 4/20 0.41
TRPV4 Q9HBA0 2/20 0.39
APLNR P35414 1/20 0.37
CA12 O43570 2/20 0.36
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
CA9 Q16790 2/20 0.36
CA14 Q9ULX7 1/20 0.36
SLC22A12 Q96S37 1/20 0.34
RORC P51449 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
LMNA P02545 1/20 0.33
HTT P42858 1/20 0.33
KMT2A Q03164 1/20 0.32
POLB P06746 1/20 0.32
SGK1 O00141 1/20 0.31
KDM4E B2RXH2 1/20 0.31
SSTR4 P31391 1/20 0.31
AGBL2 Q5U5Z8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29579603 0.84 CA2 (0.49) ALPLCA12CA1CA2CA9
SCHEMBL22532346 0.83 TRPV4 (0.38) ALPLTRPV4APLNRSLC22A12KDM4E
SCHEMBL18601131 0.82 ALPL (0.41) ALPLTRPV4CA12CA1CA2
SCHEMBL19040355 0.82 TRPV4 (0.40) ALPLTRPV4APLNRCA12CA1
SCHEMBL21802032 0.81 CA12 (0.40) ALPLCA12CA1CA2CA9
SCHEMBL18601178 0.80 PTGS2 (0.42) L3MBTL1LMNAHTTKMT2APOLB
SCHEMBL30989845 0.77 TRPV4 (0.56) TRPV4APLNRSLC22A12
SCHEMBL22531441 0.74 APLNR (0.38) TRPV4APLNRL3MBTL1KMT2AAGBL2
SCHEMBL24314192 0.72 TRPV4 (0.50) ALPLTRPV4CA12CA1CA2
SCHEMBL21713328 0.72 APLNR (0.43) TRPV4APLNRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3559007-B1 SULFONAMIDE COMPOUNDS HAVING TNAP INHIBITORY ACTIVITY DAIICHI SANKYO CO LTD (JP) 2023-08-16 EP disclosed
CN-110167946-B Sulfonamide compounds having TNAP inhibitory activity 第一三共株式会社 2022-04-08 CN disclosed
US-11046710-B2 Sulfonamide compounds DAIICHI SANKYO COMPANY, LIMITED (JP) 2021-06-29 US disclosed
US-11014939-B2 2021-05-25 US disclosed
US-20200087321-A1 SULFONAMIDE COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2020-03-19 US disclosed
EP-3559007-A1 SULFONAMIDE COMPOUNDS HAVING TNAP INHIBITORY ACTIVITY DAIICHI SANKYO COMPANY, LIMITED (JP) 2019-10-30 EP disclosed
WO-2018119444-A1 SULFONAMIDE COMPOUNDS HAVING TNAP INHIBITORY ACTIVITY DAIICHI SANKYO COMPANY, LIMITED (JP) 2018-06-28 WO disclosed
WO-2018119449-A1 OXAZEPINE DERIVATIVES HAVING TNAP INHIBITORY ACTIVITY DAIICHI SANKYO COMPANY, LIMITED (JP) 2018-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200087321-A1 SULFONAMIDE COMPOUNDS ALPI, ASAH2, STS ALPL 7/4885TRPV4 245/4885APLNR 1514/4885
US-11014939-B2 ALPI, ALPP, ACER2 ALPL 5/4885TRPV4 548/4885APLNR 593/4885
US-11046710-B2 Sulfonamide compounds ALPI, ASAH2, STS ALPL 7/4885TRPV4 245/4885APLNR 1514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.